News | July 10, 2013

Reliable Method Found to Detect Congenital Heart Disease for Babies in the Womb

Researchers analyzed 245 high-risk pregnant patients


July 10, 2013 — Researchers have announced the results of a five-year study that shows early fetal echocardiography provides reliable prenatal diagnosis of major congenital heart disease (CHD). First trimester screening looks very promising for detection of heart problems and increases the need for scheduling early and detailed cardiac evaluations.

“We were excited to find that the accuracy of prenatal cardiac screening was over 95.5 percent in our study,” said Elena Sinkovskaya, RDMS, RDCS, Ph.D., primary investigator and an assistant professor of obstetrics and gynecology at Eastern Virginia Medical School.

She and her colleagues analyzed 245 high-risk pregnant patients with prenatal and postnatal ultrasounds. The quality of images provided by the echocardiograms was sufficient to allow for a detailed evaluation of the fetal heart in the large majority of the fetuses scanned.

The study, “Fetal Cardiac Imaging in Early Pregnancy: Analysis of 254 Echocardiograms Performed Between 11+0 and 16+6 Weeks Gestation,” was presented as a poster at the 2013 American Society of Echocardiography (ASE) Annual Scientific Sessions.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now